{ "run": { "id": "cmnr133qr02wop658txw4950w", "region": "US", "assetId": "cmnr133p302wkp6586x72fp4u", "ticker": "COO", "snapshotId": "cmnr133qf02wmp658c7qo55mm", "promptTemplateId": "cmnqt07si0005lm3jzpxuu1ux", "createdAt": "2026-04-09T05:20:15.024Z", "promptTemplate": { "id": "cmnqt07si0005lm3jzpxuu1ux", "name": "Oficial 08.apr.2026", "version": 1 }, "snapshot": { "id": "cmnr133qf02wmp658c7qo55mm", "assetId": "cmnr133p302wkp6586x72fp4u", "asOf": "2026-04-08T20:00:01.000Z", "snapshot": { "asOf": "2026-04-08T20:00:01.000Z", "quote": { "asOf": "2026-04-08T20:00:01.000Z", "open": null, "price": 71.73, "dayLow": 71.11, "volume": 2194711, "dayHigh": 72.23, "currency": "USD", "prevClose": 69.66, "week52Low": 61.78, "week52High": 89.83 }, "fundamentals": { "pe": 13.1207912457912, "beta": 0.920153033198339, "epsTTM": 5.94, "fcfTTM": 206200000, "growth": { "epsYoy": -0.0456852791878173, "revenueYoy": -0.74975564460952 }, "sector": "Ophthalmic Goods", "margins": { "net": 0.1277219021579924, "gross": 0.6788399570354458, "operating": 0.2077922077922078 }, "website": "http://coopercos.com", "industry": "Medical Devices", "pegRatio": -0.543575637325638, "ebitdaTTM": 653500000, "forwardPe": 22.078611898017, "marketCap": 16200000000, "totalCash": 124900000, "totalDebt": 2499700000, "debtEquity": 0.340255337182815, "quickRatio": 0.5840696872845773, "revenueTTM": 1024100000, "companyName": "COOPER COMPANIES, INC.", "priceToBook": 0.510913289630513, "currentRatio": 1.337218775459046, "dividendYield": 0.000777623873052903, "returnOnAssets": 0.01052784082677355, "returnOnEquity": 0.0389627589129629, "analystOpinions": null, "businessSummary": "The Cooper Companies, Inc., branded as CooperCompanies, is a global medical device company headquartered in San Ramon, California. The company consists of two business units, CooperVision (CVI) which manufactures contact lenses, and CooperSurgical (CSI), which manufactures medical devices and fertility and genomic products for the women's healthcare market.", "enterpriseValue": 6306306250, "analystTargetLow": null, "analystTargetHigh": null, "analystTargetMean": null, "fullTimeEmployees": 15000, "sharesOutstanding": 195114398, "enterpriseToEbitda": 9.650047819433818, "analystTargetMedian": null, "enterpriseToRevenue": 6.157900839761742, "operatingCashflowTTM": 260900000, "analystRecommendationKey": null } }, "createdAt": "2026-04-09T05:20:15.016Z" }, "results": [ { "id": "cmnr133qu02wqp658jhkmtfq6", "runId": "cmnr133qr02wop658txw4950w", "modelId": "anthropic", "status": "SUCCESS", "rawOutput": "{\"model\":\"ai-equity-research-v1\",\"as_of\":\"2026-04-08T20:00:01.000Z\",\"ticker\":\"COO\",\"currency\":\"USD\",\"current_price\":71.73,\"target_price_6m\":75.5,\"target_price_12m\":79.0,\"recommendation\":\"BUY\",\"confidence\":0.55,\"thesis_bullets\":[\"Trading at 0.51x book value, well below medical device peers\",\"~75% YoY revenue decline suggests major divestiture or segment restructuring\",\"EV/EBITDA of 9.65x is attractive for a medical device franchise\",\"Forward P/E of 22x implies significant near-term EPS compression\",\"Gross margins remain strong at 67.9%, signaling quality franchise value\"],\"key_drivers\":[{\"driver\":\"Post-restructuring revenue stabilization and earnings normalization\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Contact lens market secular growth from myopia management\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Forward EPS compression from ~$5.94 to ~$3.25 implied\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Elevated debt of $2.5B vs $125M cash constrains flexibility\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Price-to-book discount offers margin of safety\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Operating margin of 20.8% with room for expansion post-restructuring\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Low beta (0.92) provides relative stability in volatile markets\",\"impact\":\"LOW\",\"direction\":\"POS\"},{\"driver\":\"Weak near-term FCF generation ($206M) relative to market cap\",\"impact\":\"MED\",\"direction\":\"NEG\"}],\"risks\":[\"Restructuring execution risk may delay earnings normalization beyond 12 months\",\"Leverage (~$2.5B debt) limits strategic optionality and increases vulnerability to macro shocks\",\"Forward EPS decline steeper than consensus, driving further de-rating\",\"Contact lens competitive intensity from J&J Vision and Alcon compressing margins\",\"Currency headwinds given significant international revenue exposure\"],\"assumptions\":{\"revenue_cagr_3y\":0.04,\"ebit_margin_target\":0.22,\"wacc\":0.09,\"terminal_multiple\":22.0},\"scenarios\":{\"bear\":{\"target_price\":59.0,\"prob\":0.2,\"notes\":\"Restructuring falters, EPS misses, multiple contracts to ~18x forward.\"},\"base\":{\"target_price\":79.0,\"prob\":0.55,\"notes\":\"Earnings stabilize near $3.50 forward, re-rated to ~22-23x forward P/E.\"},\"bull\":{\"target_price\":96.0,\"prob\":0.25,\"notes\":\"Faster-than-expected normalization, margin expansion drives re-rating toward 27x.\"}},\"method_notes\":\"Blended forward P/E and EV/EBITDA approach. Revenue TTM appears post-divestiture (~$1B vs historical ~$3.5B), driving anomalous YoY decline. Valued remaining franchise on normalized forward EPS of ~$3.25-3.50 at 22-27x. P/B of 0.51 provides downside cushion. Confidence capped at 0.55 due to restructuring uncertainty and data ambiguity in snapshot fundamentals. Not investment advice.\"}", "parsedJson": { "as_of": "2026-04-08T20:00:01.000Z", "model": "ai-equity-research-v1", "risks": [ "Restructuring execution risk may delay earnings normalization beyond 12 months", "Leverage (~$2.5B debt) limits strategic optionality and increases vulnerability to macro shocks", "Forward EPS decline steeper than consensus, driving further de-rating", "Contact lens competitive intensity from J&J Vision and Alcon compressing margins", "Currency headwinds given significant international revenue exposure" ], "ticker": "COO", "currency": "USD", "scenarios": { "base": { "prob": 0.55, "notes": "Earnings stabilize near $3.50 forward, re-rated to ~22-23x forward P/E.", "target_price": 79 }, "bear": { "prob": 0.2, "notes": "Restructuring falters, EPS misses, multiple contracts to ~18x forward.", "target_price": 59 }, "bull": { "prob": 0.25, "notes": "Faster-than-expected normalization, margin expansion drives re-rating toward 27x.", "target_price": 96 } }, "confidence": 0.55, "assumptions": { "wacc": 0.09, "revenue_cagr_3y": 0.04, "terminal_multiple": 22, "ebit_margin_target": 0.22 }, "key_drivers": [ { "driver": "Post-restructuring revenue stabilization and earnings normalization", "impact": "HIGH", "direction": "POS" }, { "driver": "Contact lens market secular growth from myopia management", "impact": "HIGH", "direction": "POS" }, { "driver": "Forward EPS compression from ~$5.94 to ~$3.25 implied", "impact": "HIGH", "direction": "NEG" }, { "driver": "Elevated debt of $2.5B vs $125M cash constrains flexibility", "impact": "MED", "direction": "NEG" }, { "driver": "Price-to-book discount offers margin of safety", "impact": "MED", "direction": "POS" }, { "driver": "Operating margin of 20.8% with room for expansion post-restructuring", "impact": "MED", "direction": "POS" }, { "driver": "Low beta (0.92) provides relative stability in volatile markets", "impact": "LOW", "direction": "POS" }, { "driver": "Weak near-term FCF generation ($206M) relative to market cap", "impact": "MED", "direction": "NEG" } ], "method_notes": "Blended forward P/E and EV/EBITDA approach. Revenue TTM appears post-divestiture (~$1B vs historical ~$3.5B), driving anomalous YoY decline. Valued remaining franchise on normalized forward EPS of ~$3.25-3.50 at 22-27x. P/B of 0.51 provides downside cushion. Confidence capped at 0.55 due to restructuring uncertainty and data ambiguity in snapshot fundamentals. Not investment advice.", "current_price": 71.73, "recommendation": "BUY", "thesis_bullets": [ "Trading at 0.51x book value, well below medical device peers", "~75% YoY revenue decline suggests major divestiture or segment restructuring", "EV/EBITDA of 9.65x is attractive for a medical device franchise", "Forward P/E of 22x implies significant near-term EPS compression", "Gross margins remain strong at 67.9%, signaling quality franchise value" ], "target_price_6m": 75.5, "target_price_12m": 79 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "anthropic", "webSearch": { "enabled": false, "maxToolCalls": 2, "disabledReason": null }, "pauseTurns": 0, "stopReason": "end_turn" }, "sanityIssues": [] }, "latencyMs": 50088, "createdAt": "2026-04-09T05:20:15.024Z", "usage": { "inputTokens": 3596, "outputTokens": 2163, "costUsd": 0.072055 } }, { "id": "cmnr133qu02wtp6582qqakqbo", "runId": "cmnr133qr02wop658txw4950w", "modelId": "deepseek.reasoner", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"Equity Research DCF Model\",\n \"as_of\": \"2026-04-08T20:00:01.000Z\",\n \"ticker\": \"COO\",\n \"currency\": \"USD\",\n \"current_price\": 71.73,\n \"target_price_6m\": 75.0,\n \"target_price_12m\": 80.0,\n \"recommendation\": \"BUY\",\n \"confidence\": 0.65,\n \"thesis_bullets\": [\n \"Recovery in contact lens demand post-adjustments.\",\n \"Strong margins support profitability amid volatility.\",\n \"Women's healthcare segment offers growth potential.\",\n \"Valuation attractive vs. historical multiples.\",\n \"Balanced risk from debt and competition.\"\n ],\n \"key_drivers\": [\n { \"driver\": \"Revenue growth in CooperVision\", \"impact\": \"HIGH\", \"direction\": \"POS\" },\n { \"driver\": \"Margin stability and efficiency\", \"impact\": \"MED\", \"direction\": \"POS\" },\n { \"driver\": \"Debt reduction and financial health\", \"impact\": \"MED\", \"direction\": \"POS\" },\n { \"driver\": \"Regulatory approvals for new products\", \"impact\": \"HIGH\", \"direction\": \"POS\" },\n { \"driver\": \"Competitive pressure in contact lenses\", \"impact\": \"MED\", \"direction\": \"NEG\" },\n { \"driver\": \"Economic sensitivity of elective procedures\", \"impact\": \"LOW\", \"direction\": \"NEG\" },\n { \"driver\": \"Currency fluctuations from global operations\", \"impact\": \"LOW\", \"direction\": \"NEG\" }\n ],\n \"risks\": [\n \"Further revenue decline in core segments.\",\n \"Increased debt burden affecting flexibility.\",\n \"Regulatory hurdles in medical devices.\",\n \"Market saturation in contact lenses.\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.05,\n \"ebit_margin_target\": 0.21,\n \"wacc\": 0.085,\n \"terminal_multiple\": 10.0\n },\n \"scenarios\": {\n \"bear\": { \"target_price\": 65.0, \"prob\": 0.2, \"notes\": \"Continued revenue decline and margin pressure.\" },\n \"base\": { \"target_price\": 80.0, \"prob\": 0.6, \"notes\": \"Moderate recovery and stable margins.\" },\n \"bull\": { \"target_price\": 90.0, \"prob\": 0.2, \"notes\": \"Strong growth in both segments and multiple expansion.\" }\n },\n \"method_notes\": \"Valuation based on DCF with assumed recovery in revenue growth. Recommendation BUY due to ~11.5% upside to 12M target. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:01.000Z", "model": "Equity Research DCF Model", "risks": [ "Further revenue decline in core segments.", "Increased debt burden affecting flexibility.", "Regulatory hurdles in medical devices.", "Market saturation in contact lenses." ], "ticker": "COO", "currency": "USD", "scenarios": { "base": { "prob": 0.6, "notes": "Moderate recovery and stable margins.", "target_price": 80 }, "bear": { "prob": 0.2, "notes": "Continued revenue decline and margin pressure.", "target_price": 65 }, "bull": { "prob": 0.2, "notes": "Strong growth in both segments and multiple expansion.", "target_price": 90 } }, "confidence": 0.65, "assumptions": { "wacc": 0.085, "revenue_cagr_3y": 0.05, "terminal_multiple": 10, "ebit_margin_target": 0.21 }, "key_drivers": [ { "driver": "Revenue growth in CooperVision", "impact": "HIGH", "direction": "POS" }, { "driver": "Margin stability and efficiency", "impact": "MED", "direction": "POS" }, { "driver": "Debt reduction and financial health", "impact": "MED", "direction": "POS" }, { "driver": "Regulatory approvals for new products", "impact": "HIGH", "direction": "POS" }, { "driver": "Competitive pressure in contact lenses", "impact": "MED", "direction": "NEG" }, { "driver": "Economic sensitivity of elective procedures", "impact": "LOW", "direction": "NEG" }, { "driver": "Currency fluctuations from global operations", "impact": "LOW", "direction": "NEG" } ], "method_notes": "Valuation based on DCF with assumed recovery in revenue growth. Recommendation BUY due to ~11.5% upside to 12M target. Not investment advice.", "current_price": 71.73, "recommendation": "BUY", "thesis_bullets": [ "Recovery in contact lens demand post-adjustments.", "Strong margins support profitability amid volatility.", "Women's healthcare segment offers growth potential.", "Valuation attractive vs. historical multiples.", "Balanced risk from debt and competition." ], "target_price_6m": 75, "target_price_12m": 80 }, "errorsJson": { "attempts": [ { "error": "provider_error: terminated", "attempt": 0, "rawOutputTruncated": null } ], "providerMeta": { "endpoint": "https://api.deepseek.com/v1/chat/completions", "provider": "deepseek", "webSearch": { "enabled": false, "supported": false }, "responseFormat": "json_object" }, "sanityIssues": [] }, "latencyMs": 343, "createdAt": "2026-04-09T05:20:15.024Z", "usage": { "inputTokens": 2102, "outputTokens": 3061, "costUsd": 0.001874 } }, { "id": "cmnr133qu02wrp658ew49piiy", "runId": "cmnr133qr02wop658txw4950w", "modelId": "gemini.3-pro", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"AI Model Recommendation\",\n \"as_of\": \"2026-04-08T20:00:01.000Z\",\n \"ticker\": \"COO\",\n \"currency\": \"USD\",\n \"current_price\": 71.73,\n \"target_price_6m\": 75.00,\n \"target_price_12m\": 78.00,\n \"recommendation\": \"BUY\",\n \"confidence\": 0.65,\n \"thesis_bullets\": [\n \"Resilient contact lens demand provides stable recurring revenue despite macro pressures.\",\n \"Myopia management portfolio offers a strong long-term structural growth runway.\",\n \"CooperSurgical faces near-term headwinds but maintains solid market share in fertility.\",\n \"Forward P/E of 22x reflects expected earnings compression but captures recovery potential.\",\n \"Strong gross margins insulate against moderate inflationary supply chain pressures.\"\n ],\n \"key_drivers\": [\n {\n \"driver\": \"Daily silicone hydrogel adoption\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Myopia management growth\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Fertility clinic volumes\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Foreign exchange headwinds\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Raw material inflation\",\n \"impact\": \"LOW\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Debt reduction and interest expense\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n }\n ],\n \"risks\": [\n \"Down-trading from daily to reusable lenses during economic downturns.\",\n \"Integration risks from recent CooperSurgical acquisitions.\",\n \"Intense competition from Alcon and J&J in the vision care market.\",\n \"Regulatory hurdles for new myopia control products.\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.05,\n \"ebit_margin_target\": 0.22,\n \"wacc\": 0.085,\n \"terminal_multiple\": 18.0\n },\n \"scenarios\": {\n \"bear\": {\n \"target_price\": 65.00,\n \"prob\": 0.2,\n \"notes\": \"Macro slowdown causes down-trading in lenses and delays in elective fertility treatments.\"\n },\n \"base\": {\n \"target_price\": 78.00,\n \"prob\": 0.6,\n \"notes\": \"Steady transition to daily lenses and sustained myopia management growth drive moderate earnings expansion.\"\n },\n \"bull\": {\n \"target_price\": 90.00,\n \"prob\": 0.2,\n \"notes\": \"Accelerated myopia product adoption and strong surgical recovery lead to multiple expansion.\"\n }\n },\n \"method_notes\": \"Valuation based on a DCF model and EV/EBITDA multiples, reflecting steady vision care growth offset by near-term surgical headwinds. The probability-weighted scenario target implies an 8.5% upside, supporting a BUY rating. This is not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:01.000Z", "model": "AI Model Recommendation", "risks": [ "Down-trading from daily to reusable lenses during economic downturns.", "Integration risks from recent CooperSurgical acquisitions.", "Intense competition from Alcon and J&J in the vision care market.", "Regulatory hurdles for new myopia control products." ], "ticker": "COO", "currency": "USD", "scenarios": { "base": { "prob": 0.6, "notes": "Steady transition to daily lenses and sustained myopia management growth drive moderate earnings expansion.", "target_price": 78 }, "bear": { "prob": 0.2, "notes": "Macro slowdown causes down-trading in lenses and delays in elective fertility treatments.", "target_price": 65 }, "bull": { "prob": 0.2, "notes": "Accelerated myopia product adoption and strong surgical recovery lead to multiple expansion.", "target_price": 90 } }, "confidence": 0.65, "assumptions": { "wacc": 0.085, "revenue_cagr_3y": 0.05, "terminal_multiple": 18, "ebit_margin_target": 0.22 }, "key_drivers": [ { "driver": "Daily silicone hydrogel adoption", "impact": "HIGH", "direction": "POS" }, { "driver": "Myopia management growth", "impact": "MED", "direction": "POS" }, { "driver": "Fertility clinic volumes", "impact": "MED", "direction": "POS" }, { "driver": "Foreign exchange headwinds", "impact": "MED", "direction": "NEG" }, { "driver": "Raw material inflation", "impact": "LOW", "direction": "NEG" }, { "driver": "Debt reduction and interest expense", "impact": "MED", "direction": "POS" } ], "method_notes": "Valuation based on a DCF model and EV/EBITDA multiples, reflecting steady vision care growth offset by near-term surgical headwinds. The probability-weighted scenario target implies an 8.5% upside, supporting a BUY rating. This is not investment advice.", "current_price": 71.73, "recommendation": "BUY", "thesis_bullets": [ "Resilient contact lens demand provides stable recurring revenue despite macro pressures.", "Myopia management portfolio offers a strong long-term structural growth runway.", "CooperSurgical faces near-term headwinds but maintains solid market share in fertility.", "Forward P/E of 22x reflects expected earnings compression but captures recovery potential.", "Strong gross margins insulate against moderate inflationary supply chain pressures." ], "target_price_6m": 75, "target_price_12m": 78 }, "errorsJson": { "attempts": [ { "error": "sanity_error: buy_scenario_return_too_low: BUY requires >= 6% return from probability-weighted scenarios.", "attempt": 0, "rawOutputTruncated": "{\n \"model\": \"AI Model Recommendation\",\n \"as_of\": \"2026-04-08T20:00:01.000Z\",\n \"ticker\": \"COO\",\n \"currency\": \"USD\",\n \"current_price\": 71.73,\n \"target_price_6m\": 75.00,\n \"target_price_12m\": 78.00,\n \"recommendation\": \"BUY\",\n \"confidence\": 0.65,\n \"thesis_bullets\": [\n \"Resilient contact lens demand provides stable recurring revenue despite macro pressures.\",\n \"Myopia management portfolio offers a strong long-term structural growth runway.\",\n \"CooperSurgical faces near-term headwinds but maintains solid market share in fertility.\",\n \"Forward P/E of 22x reflects expected earnings compression but captures recovery potential.\",\n \"Strong gross margins insulate against moderate inflationary supply chain pressures.\"\n ],\n \"key_drivers\": [\n {\n \"driver\": \"Daily silicone hydrogel adoption\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Myopia management growth\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Fertility clinic volumes\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Foreign exchange headwinds\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n…" } ], "providerMeta": { "model": "gemini-3-pro-preview", "provider": "gemini", "webSearch": { "used": false, "allowed": false, "enabled": false, "requested": false, "disabledReason": null } }, "sanityIssues": [] }, "latencyMs": 18243, "createdAt": "2026-04-09T05:20:15.024Z", "usage": { "inputTokens": 3155, "outputTokens": 808, "costUsd": 0.016006 } }, { "id": "cmnr133qu02wpp658niwu0yct", "runId": "cmnr133qr02wop658txw4950w", "modelId": "openai.gpt-5.4", "status": "SUCCESS", "rawOutput": "{\"model\":\"AI Model Recommendation v2\",\"as_of\":\"2026-04-08T20:00:01.000Z\",\"ticker\":\"COO\",\"currency\":\"USD\",\"current_price\":71.73,\"target_price_6m\":74.4,\"target_price_12m\":75.8,\"recommendation\":\"HOLD\",\"confidence\":0.58,\"thesis_bullets\":[\"Contact lens demand benefits from premium silicone hydrogel, toric, and myopia-management adoption.\",\"Gross margin near 68% and operating margin near 21% support earnings durability.\",\"EPS slipped year over year, signaling limited near-term operating leverage.\",\"Debt is manageable, but modest liquidity constrains flexibility if demand softens.\",\"At 13.1x TTM EPS, shares screen roughly fairly valued amid mixed fundamentals.\"],\"key_drivers\":[{\"driver\":\"Premium lens mix\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Toric and myopia adoption\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"CooperSurgical recovery\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Margin retention\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"EPS trend stabilization\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Leverage and liquidity\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Reported revenue volatility\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"FX exposure\",\"impact\":\"LOW\",\"direction\":\"NEG\"}],\"risks\":[\"CooperSurgical fertility and genomics weakness persists.\",\"Competitive pricing pressures contact lens growth.\",\"Regulatory or product quality issues disrupt sales.\",\"Higher rates keep financing costs elevated.\",\"Snapshot data inconsistencies may mask true trends.\"],\"assumptions\":{\"revenue_cagr_3y\":0.055,\"ebit_margin_target\":0.215,\"wacc\":0.085,\"terminal_multiple\":14},\"scenarios\":{\"bear\":{\"target_price\":62,\"prob\":0.25,\"notes\":\"Surgical recovery lags and margin pressure persists.\"},\"base\":{\"target_price\":76,\"prob\":0.5,\"notes\":\"Lens mix offsets softer procedures and supports steady earnings.\"},\"bull\":{\"target_price\":88,\"prob\":0.25,\"notes\":\"Premium lens adoption and CSI recovery re-rate shares.\"}},\"method_notes\":\"Base case blends normalized P/E and EV/EBITDA using snapshot margins and cash flow. Snapshot includes anomalous revenue/EV data, so confidence is moderated and valuation stays near fair value. No sell-side targets used; not investment advice.\"}", "parsedJson": { "as_of": "2026-04-08T20:00:01.000Z", "model": "AI Model Recommendation v2", "risks": [ "CooperSurgical fertility and genomics weakness persists.", "Competitive pricing pressures contact lens growth.", "Regulatory or product quality issues disrupt sales.", "Higher rates keep financing costs elevated.", "Snapshot data inconsistencies may mask true trends." ], "ticker": "COO", "currency": "USD", "scenarios": { "base": { "prob": 0.5, "notes": "Lens mix offsets softer procedures and supports steady earnings.", "target_price": 76 }, "bear": { "prob": 0.25, "notes": "Surgical recovery lags and margin pressure persists.", "target_price": 62 }, "bull": { "prob": 0.25, "notes": "Premium lens adoption and CSI recovery re-rate shares.", "target_price": 88 } }, "confidence": 0.58, "assumptions": { "wacc": 0.085, "revenue_cagr_3y": 0.055, "terminal_multiple": 14, "ebit_margin_target": 0.215 }, "key_drivers": [ { "driver": "Premium lens mix", "impact": "HIGH", "direction": "POS" }, { "driver": "Toric and myopia adoption", "impact": "MED", "direction": "POS" }, { "driver": "CooperSurgical recovery", "impact": "MED", "direction": "POS" }, { "driver": "Margin retention", "impact": "HIGH", "direction": "POS" }, { "driver": "EPS trend stabilization", "impact": "MED", "direction": "POS" }, { "driver": "Leverage and liquidity", "impact": "MED", "direction": "NEG" }, { "driver": "Reported revenue volatility", "impact": "HIGH", "direction": "NEG" }, { "driver": "FX exposure", "impact": "LOW", "direction": "NEG" } ], "method_notes": "Base case blends normalized P/E and EV/EBITDA using snapshot margins and cash flow. Snapshot includes anomalous revenue/EV data, so confidence is moderated and valuation stays near fair value. No sell-side targets used; not investment advice.", "current_price": 71.73, "recommendation": "HOLD", "thesis_bullets": [ "Contact lens demand benefits from premium silicone hydrogel, toric, and myopia-management adoption.", "Gross margin near 68% and operating margin near 21% support earnings durability.", "EPS slipped year over year, signaling limited near-term operating leverage.", "Debt is manageable, but modest liquidity constrains flexibility if demand softens.", "At 13.1x TTM EPS, shares screen roughly fairly valued amid mixed fundamentals." ], "target_price_6m": 74.4, "target_price_12m": 75.8 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "openai", "webSearch": { "used": false, "enabled": false, "sources": [], "maxToolCalls": 2 }, "responseId": "resp_083c7528c24c3e770069d7576f479c8190998e98171988de68", "reasoningEffort": "medium", "structuredOutputs": { "used": true, "requested": true, "disabledReason": null } }, "sanityIssues": [] }, "latencyMs": 41202, "createdAt": "2026-04-09T05:20:15.024Z", "usage": { "inputTokens": 2372, "outputTokens": 2303, "costUsd": 0.036393 } }, { "id": "cmnr133qu02wsp658kn92irgw", "runId": "cmnr133qr02wop658txw4950w", "modelId": "xai.grok-4.20-reasoning", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"AI Analyst DCF Model\",\n \"as_of\": \"2026-04-08T20:00:01.000Z\",\n \"ticker\": \"COO\",\n \"currency\": \"USD\",\n \"current_price\": 71.73,\n \"target_price_6m\": 78,\n \"target_price_12m\": 85,\n \"recommendation\": \"BUY\",\n \"confidence\": 0.62,\n \"thesis_bullets\": [\n \"Core contact lens business generates strong cash flow despite recent dip.\",\n \"CooperSurgical expansion into fertility offers significant growth potential.\",\n \"Current valuation attractive given stable margins and market position.\",\n \"High debt and negative YOY growth present near-term challenges.\",\n \"Balanced outlook with upside from innovation offset by execution risks.\"\n ],\n \"key_drivers\": [\n {\n \"driver\": \"Contact lens demand recovery\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Fertility market expansion\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Product innovation pipeline\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Recent negative revenue growth\",\n \"impact\": \"HIGH\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Elevated debt levels\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Operating margin stability\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Competitive intensity\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Regulatory environment\",\n \"impact\": \"LOW\",\n \"direction\": \"NEG\"\n }\n ],\n \"risks\": [\n \"Prolonged slowdown in elective surgeries\",\n \"Intensifying competition in vision care\",\n \"Integration challenges in acquisitions\",\n \"Interest rate sensitivity on variable debt\",\n \"Currency and geopolitical risks\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.05,\n \"ebit_margin_target\": 0.22,\n \"wacc\": 0.085,\n \"terminal_multiple\": 16\n },\n \"scenarios\": {\n \"bear\": {\n \"target_price\": 62,\n \"prob\": 0.25,\n \"notes\": \"Continued revenue weakness and margin erosion.\"\n },\n \"base\": {\n \"target_price\": 85,\n \"prob\": 0.5,\n \"notes\": \"Moderate growth recovery to historical trends.\"\n },\n \"bull\": {\n \"target_price\": 105,\n \"prob\": 0.25,\n \"notes\": \"Accelerated adoption of new products and segments.\"\n }\n },\n \"method_notes\": \"Valuation via DCF with given assumptions; 18% 12M upside supports BUY despite mixed YOY growth and snapshot EV inconsistency. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:01.000Z", "model": "AI Analyst DCF Model", "risks": [ "Prolonged slowdown in elective surgeries", "Intensifying competition in vision care", "Integration challenges in acquisitions", "Interest rate sensitivity on variable debt", "Currency and geopolitical risks" ], "ticker": "COO", "currency": "USD", "scenarios": { "base": { "prob": 0.5, "notes": "Moderate growth recovery to historical trends.", "target_price": 85 }, "bear": { "prob": 0.25, "notes": "Continued revenue weakness and margin erosion.", "target_price": 62 }, "bull": { "prob": 0.25, "notes": "Accelerated adoption of new products and segments.", "target_price": 105 } }, "confidence": 0.62, "assumptions": { "wacc": 0.085, "revenue_cagr_3y": 0.05, "terminal_multiple": 16, "ebit_margin_target": 0.22 }, "key_drivers": [ { "driver": "Contact lens demand recovery", "impact": "HIGH", "direction": "POS" }, { "driver": "Fertility market expansion", "impact": "HIGH", "direction": "POS" }, { "driver": "Product innovation pipeline", "impact": "MED", "direction": "POS" }, { "driver": "Recent negative revenue growth", "impact": "HIGH", "direction": "NEG" }, { "driver": "Elevated debt levels", "impact": "MED", "direction": "NEG" }, { "driver": "Operating margin stability", "impact": "MED", "direction": "POS" }, { "driver": "Competitive intensity", "impact": "MED", "direction": "NEG" }, { "driver": "Regulatory environment", "impact": "LOW", "direction": "NEG" } ], "method_notes": "Valuation via DCF with given assumptions; 18% 12M upside supports BUY despite mixed YOY growth and snapshot EV inconsistency. Not investment advice.", "current_price": 71.73, "recommendation": "BUY", "thesis_bullets": [ "Core contact lens business generates strong cash flow despite recent dip.", "CooperSurgical expansion into fertility offers significant growth potential.", "Current valuation attractive given stable margins and market position.", "High debt and negative YOY growth present near-term challenges.", "Balanced outlook with upside from innovation offset by execution risks." ], "target_price_6m": 78, "target_price_12m": 85 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "xai", "webSearch": { "used": false, "enabled": false, "sources": [], "maxToolCalls": 2 }, "responseId": "0566a574-5ac0-96e4-a45e-5c6a3dc1f6bb", "usedFallbackChatCompletions": false }, "sanityIssues": [] }, "latencyMs": 24913, "createdAt": "2026-04-09T05:20:15.024Z", "usage": { "inputTokens": 2711, "outputTokens": 3883, "costUsd": 0.066378 } } ] } }